[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Shibata Y, Baba E, Ariyama H, Miki R, Ogami N, Arita S, Qin B, Kusaba H, Mitsugi K, Noshiro H, Yao T, Nakano S: Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin. World J Gastroenterol; 2007 Jul 14;13(26):3634-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.
  • Basaloid squamous cell carcinoma (BSC) of the esophagus is a rare malignant disease.
  • A 57-year-old woman was diagnosed as having squamous cell carcinoma of the esophagus upon endoscopic examination.
  • The pathological diagnosis of the surgical specimen was BSC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Splenic Neoplasms / drug therapy. Splenic Neoplasms / secondary. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2000;30(2):163-7 [10664341.001]
  • [Cites] Hepatogastroenterology. 1999 Sep-Oct;46(29):2868-71 [10576363.001]
  • [Cites] Jpn J Clin Oncol. 2001 Sep;31(9):419-23 [11689594.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):120-4 [11755833.001]
  • [Cites] Surg Today. 2003;33(6):444-7 [12768371.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):955-9 [15151954.001]
  • [Cites] Cancer Treat Rev. 2004 Aug;30(5):473-7 [15245779.001]
  • [Cites] Int Adv Surg Oncol. 1980;3:73-109 [6926744.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):537-42 [2364364.001]
  • [Cites] Acta Pathol Jpn. 1991 Jan;41(1):59-64 [2031457.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(4):273-6 [1537072.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):479-84 [8621231.001]
  • [Cites] Cancer. 1997 May 15;79(10):1871-8 [9149011.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 May;83(5):584-7 [9159819.001]
  • [Cites] Oncol Res. 1997;9(4):167-72 [9268987.001]
  • [Cites] Surg Today. 1997;27(8):685-91 [9306579.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1027-32 [10514383.001]
  • [Cites] Dis Esophagus. 2006;19(6):473-6 [17069591.001]
  • [Cites] Histopathology. 2000 Apr;36(4):331-40 [10759947.001]
  • (PMID = 17659717.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4146806
  •  go-up   go-down


2. Záruba K, Králová J, Rezanka P, Poucková P, Veverková L, Král V: Modified porphyrin-brucine conjugated to gold nanoparticles and their application in photodynamic therapy. Org Biomol Chem; 2010 Jul 21;8(14):3202-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two porphyrin-brucine quaternary ammonium salts were immobilized on gold nanoparticles and their suitability for both in vitro and in vivo photodynamic therapy (PDT) was assayed using the basaloid squamous cell carcinoma PE/CA-PJ34 cell line.
  • [MeSH-minor] Alkylation. Animals. Biological Transport. Cell Death / drug effects. Cell Death / radiation effects. Cell Line, Tumor. Humans. Intracellular Space / metabolism. Mice. Neoplasms / drug therapy. Solvents / chemistry

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BRUCINE .
  • Hazardous Substances Data Bank. STRYCHNINE .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20485822.001).
  • [ISSN] 1477-0539
  • [Journal-full-title] Organic & biomolecular chemistry
  • [ISO-abbreviation] Org. Biomol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Porphyrins; 0 / Solvents; 6NG17YCK6H / brucine; 7440-57-5 / Gold; H9Y79VD43J / Strychnine
  •  go-up   go-down


3. Xu S, Wang X, Xu W, Xia Y, Zhang C: Evaluation of photodynamic therapy of skin cancers with partial differential alpha-aminolevulinic acid. Chin Med J (Engl); 2002 Aug;115(8):1141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eighty-eight patients, including 34 cases of basal cell carcinoma (BCC), 32 cases of squamous cell carcinoma (SCC), two cases of basal-squamous cell carcinoma (BSCC), one case of verrucuous carcinoma, nine cases of Bowen disease, two cases Paget disease of the nipple and eight cases of extramammary Paget disease, were treated by the partial differential alpha-aminolevulinic acid induced photodynamic therapy first in China from 1997 to 2000.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12215278.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


Advertisement
4. Morton L, Omar R, Carroll S, Beirne M, Halliday D, Taylor KM: Incomplete and inaccurate death certification--the impact on research. J Public Health Med; 2000 Jun;22(2):133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The objectives of this study were (1) to investigate the extent of erroneous and/or omitted information on death certificates of patients-implanted with Bjork-Shiley Convexo-Concave (BSCC) heart valves;.
  • METHODS: A review was carried out of death certificates and clinical notes for patients implanted in the United Kingdom with BSCC valves.
  • This was a multicentre study (38 hospitals) based at the Cardiothoracic Department, NHLI, Imperial College School of Medicine at Hammersmith Hospital, London.
  • The subjects were 478 patients implanted with a BSCC valve between 1979 and 1986 who died in the following years: 1984, 1987, 1990, 1993 and 1996.
  • CONCLUSIONS: The relatively high number of death certificates that do not record the presence of a valve prosthesis and the observed under-reporting of post mortems may lead to inaccurate reporting of the number of BSCC valves that fail.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10912549.001).
  • [ISSN] 0957-4832
  • [Journal-full-title] Journal of public health medicine
  • [ISO-abbreviation] J Public Health Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  •  go-up   go-down


5. Karatzanis AD, Fragkiadakis GM, Prokopakis EP, Koutsopoulos AV, Helidonis ES, Velegrakis GA: Basaloid squamous cell carcinoma of the soft palate: case report. Auris Nasus Larynx; 2008 Dec;35(4):592-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the soft palate: case report.
  • Basaloid squamous cell carcinoma (BSCC) is a histologically distinct variant of squamous cell carcinoma.
  • The palate is a very rare site of BSCC development and only three cases have been reported in the international literature.
  • In this report, we present a case of basaloid squamous cell carcinoma of the soft palate.
  • The therapeutic strategy and histological findings are described in detail, including immunohistochemistry with the use of involucrin, an agent used for the first time for BSCC diagnosis.
  • [MeSH-major] Carcinoma, Basosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Palatal Neoplasms / diagnosis. Palate, Soft
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Biopsy. Coloring Agents. Diagnosis, Differential. Humans. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Protein Precursors. Radiotherapy, Adjuvant. Reoperation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18242906.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Coloring Agents; 0 / Protein Precursors; 60108-77-2 / involucrin
  •  go-up   go-down


6. Wang HM, Ng SH, Wang CH, Liaw CT, Chen JS, Yang TS, Chen IH: Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa. Anticancer Drugs; 2001 Apr;12(4):331-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa.
  • From July 1994 to December 1996, 41 patients with previously untreated, advanced bulky squamous cell carcinoma arising from the buccal mucosa (BSCC) were enrolled.
  • The tumor extent was stage III/IV: three of 38, T4: 85%, N2-3: 20%.
  • Using i.a. chemotherapy as a cytoreductive therapy followed by subsequent i.v. chemotherapy produces a high response rate and an encouraging degree of complete response rate in advanced bulky BSCC.
  • However, toxicity management and catheter placement will need to be improved in order to better define the role of this therapy in advanced BSCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Alopecia / chemically induced. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Eruptions / etiology. Dyspnea / chemically induced. Dyspnea / drug therapy. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial / methods. Infusions, Intravenous / methods. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Middle Aged. Mouth Mucosa. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Stomatitis / chemically induced. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11335789.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Chernock RD, Lewis JS Jr, Zhang Q, El-Mofty SK: Human papillomavirus-positive basaloid squamous cell carcinomas of the upper aerodigestive tract: a distinct clinicopathologic and molecular subtype of basaloid squamous cell carcinoma. Hum Pathol; 2010 Jul;41(7):1016-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-positive basaloid squamous cell carcinomas of the upper aerodigestive tract: a distinct clinicopathologic and molecular subtype of basaloid squamous cell carcinoma.
  • Basaloid squamous cell carcinoma of the upper aerodigestive tract is a rare, morphologically distinct variant of squamous cell carcinoma that is thought to be clinically aggressive.
  • The histologic features are distinct from, but often confused with, those of human papillomavirus-related oropharyngeal nonkeratinizing squamous cell carcinoma.
  • The role of human papillomavirus as an etiologic agent in true basaloid squamous cell carcinoma is controversial.
  • The purpose of this study was to determine human papillomavirus prevalence and its clinicopathologic significance in upper aerodigestive tract tumors with true basaloid squamous cell carcinoma histology.
  • Overall survival was better for human papillomavirus-positive basaloid squamous cell carcinomas (P < .05), with 86% of patients alive at 3 years compared with 35.3% of patients with human papillomavirus-negative tumors.
  • These findings suggest that a subset of basaloid squamous cell carcinomas is virally driven.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Hypopharyngeal Neoplasms / virology. Laryngeal Neoplasms / virology. Oropharyngeal Neoplasms / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1463-70 [14576481.001]
  • [Cites] Head Neck Pathol. 2008 Jun;2(2):83-91 [20614328.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):83-6 [14732774.001]
  • [Cites] Laryngoscope. 2004 Jun;114(6):1063-8 [15179214.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):537-42 [2364364.001]
  • [Cites] Am J Surg Pathol. 1992 Oct;16(10):939-46 [1384369.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):595-604 [9028373.001]
  • [Cites] J Korean Med Sci. 1998 Jun;13(3):269-74 [9681804.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):841-54 [10091761.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):736-47 [16401683.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):339-45 [16504868.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14152-7 [16959885.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2620-3 [16991119.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1418-25 [17205528.001]
  • [Cites] Head Neck. 2003 Nov;25(11):904-10 [14603450.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2000;257(3):154-7 [10839489.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):300-4 [10861508.001]
  • [Cites] Laryngoscope. 2000 Sep;110(9):1479-82 [10983946.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):120-4 [11755833.001]
  • [Cites] J Clin Pathol. 2002 Nov;55(11):834-40 [12401821.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):336-44 [12569557.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):747-53 [12598309.001]
  • [Cites] Am J Otolaryngol. 2003 May-Jun;24(3):204-8 [12761712.001]
  • [Cites] Oral Oncol. 2007 Apr;43(4):327-32 [16979930.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(2):244-50 [18096379.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2698-709 [18429002.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1044-50 [18496144.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):6213-21 [19884544.001]
  • [Cites] Head Neck Pathol. 2009 Sep;3(3):186-94 [20596971.001]
  • [CommentIn] Hum Pathol. 2010 Oct;41(10):1505-6; author reply 1506 [20868902.001]
  • (PMID = 20236687.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA091842; United States / NCI NIH HHS / CA / P30 CA091842
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS534623; NLM/ PMC3873737
  •  go-up   go-down


8. Sonegawa H, Nukui T, Li DW, Takaishi M, Sakaguchi M, Huh NH: Involvement of deterioration in S100C/A11-mediated pathway in resistance of human squamous cancer cell lines to TGFbeta-induced growth suppression. J Mol Med (Berl); 2007 Jul;85(7):753-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of deterioration in S100C/A11-mediated pathway in resistance of human squamous cancer cell lines to TGFbeta-induced growth suppression.
  • In the present study, we examined the possible deterioration in the pathway in human squamous cancer cell lines, focusing on intracellular localization of S100C/A11 and its functional partners Smad3 and Smad4.
  • All four human squamous cancer cell lines examined (A431, BSCC-93, DJM-1, and HSC-5) were resistant to growth suppression by TGFbeta.
  • In BSCC-93, DJM-1, and HSC-5 cells exposed to TGFbeta, S100C/A11 was not transferred to the nuclei, and p21(WAF1) was not induced.
  • These results indicate that the deterioration in the S100C/A11-mediated pathway conferred upon the cancer cell lines resistance to TGFbeta.
  • Thus, the newly found S100C/A11-mediated pathway is at least partly involved in conferring upon human squamous cell cancers resistant to TGFbeta-induced growth suppression, which is considered to play a critical role for the initiation and progression of many human cancers.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Division / drug effects. Drug Resistance, Neoplasm / drug effects. Smad3 Protein / metabolism. Smad4 Protein / metabolism. Transforming Growth Factor beta / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Gene Expression Regulation / drug effects. Humans. Protein Transport. Signal Transduction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14949-54 [10611318.001]
  • [Cites] Cell Calcium. 1997 Oct;22(4):243-54 [9481475.001]
  • [Cites] Int J Surg Pathol. 2004 Apr;12(2):107-15 [15173915.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8671-8 [16204035.001]
  • [Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]
  • [Cites] Int J Cancer. 2005 Aug 20;116(2):285-90 [15800916.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6076-80 [7687059.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5564-9 [15313892.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4877-82 [9234744.001]
  • [Cites] Curr Top Dev Biol. 1987;22:5-34 [2443316.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1473-9 [11076656.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):769-74 [10952782.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):606-11 [15701847.001]
  • [Cites] Oncology. 2004;66(6):429-38 [15452371.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7853-8 [10884415.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1478-84 [12404222.001]
  • [Cites] Oncogene. 2004 Jul 15;23 (32):5487-95 [15122322.001]
  • [Cites] Histopathology. 2005 Mar;46(3):256-69 [15720411.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3638-46 [10612291.001]
  • [Cites] J Cell Biol. 2003 Nov 24;163(4):825-35 [14623863.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3395-405 [15150091.001]
  • [Cites] Cancer Sci. 2003 Mar;94(3):230-4 [12824914.001]
  • [Cites] J Pathol. 2002 Mar;196 (3):292-9 [11857492.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4685-95 [11498791.001]
  • [Cites] EMBO J. 1998 Jul 15;17(14):4056-65 [9670020.001]
  • [Cites] J Cell Biol. 2004 Mar 29;164(7):979-84 [15051732.001]
  • [Cites] Cancer Lett. 1995 Mar 2;89(2):195-200 [7889529.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):253-62 [14710237.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3218-25 [15833853.001]
  • [Cites] J Pathol. 2003 Sep;201(1):63-74 [12950018.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2649-57 [12750293.001]
  • [Cites] Biochem Cell Biol. 2004 Aug;82(4):508-15 [15284904.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7999-8004 [11691825.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2397-405 [15059891.001]
  • [Cites] Oncogene. 2000 Dec 14;19(54):6334-41 [11175348.001]
  • [Cites] Proteomics. 2003 Oct;3(10):1988-2001 [14625861.001]
  • [Cites] Front Biosci. 2002 May 01;7:d1356-68 [11991838.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92 (11):1955-8 [15900299.001]
  • [Cites] Mol Hum Reprod. 2004 Oct;10(10):735-42 [15322223.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6733-8 [9618481.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1287-93 [15138568.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1595-603 [10749128.001]
  • [Cites] J Biol Chem. 1991 Oct 5;266(28):18668-73 [1917990.001]
  • [Cites] Int J Cancer. 1999 Aug 27;82(5):754-8 [10417776.001]
  • [Cites] Hum Pathol. 2004 Nov;35(11):1385-91 [15668896.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13921-6 [16172401.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6823-6 [12460893.001]
  • (PMID = 17476473.001).
  • [ISSN] 0946-2716
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / SMAD3 protein, human; 0 / SMAD4 protein, human; 0 / Smad3 Protein; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta
  •  go-up   go-down


9. Wu C, Herman BA, Retta SM, Grossman LW, Liu JS, Hwang NH: On the closing sounds of a mechanical heart valve. Ann Biomed Eng; 2005 Jun;33(6):743-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Food and Drug Administration (FDA), in-vitro testing is required to evaluate the potential for cavitation damage of a mechanical heart valve (MHV).
  • In the present study, the frequency characteristics of the closing sound in air of a Björk-Shiley Convexo-Concave (BSCC) valve are investigated.
  • It is found that for the BSCC valve tested, the distribution of the sound energy over its frequency domain changes at different valve closing speeds, but the cut-off frequency remains unchanged at 123.32 +/- 6.12 kHz.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078614.001).
  • [ISSN] 0090-6964
  • [Journal-full-title] Annals of biomedical engineering
  • [ISO-abbreviation] Ann Biomed Eng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement